Goldman Sachs Group Inc. Has $148,000 Stock Position in Nautilus Biotechnology, Inc. $NAUT

Goldman Sachs Group Inc. reduced its stake in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) by 12.2% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 171,787 shares of the company’s stock after selling 23,908 shares during the period. Goldman Sachs Group Inc. owned approximately 0.14% of Nautilus Biotechnology worth $148,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Squarepoint Ops LLC acquired a new stake in Nautilus Biotechnology during the 4th quarter worth approximately $44,000. XTX Topco Ltd bought a new position in shares of Nautilus Biotechnology during the 1st quarter worth approximately $31,000. Millennium Management LLC bought a new position in shares of Nautilus Biotechnology during the 4th quarter worth approximately $63,000. Fayez Sarofim & Co bought a new position in shares of Nautilus Biotechnology during the 1st quarter worth approximately $39,000. Finally, Bank of America Corp DE grew its stake in shares of Nautilus Biotechnology by 37.1% during the 4th quarter. Bank of America Corp DE now owns 49,419 shares of the company’s stock worth $83,000 after acquiring an additional 13,363 shares in the last quarter. 50.71% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Nautilus Biotechnology

In other Nautilus Biotechnology news, CEO Sujal M. Patel purchased 116,500 shares of the firm’s stock in a transaction dated Friday, September 5th. The stock was bought at an average cost of $0.67 per share, with a total value of $78,055.00. Following the purchase, the chief executive officer directly owned 10,258,221 shares of the company’s stock, valued at $6,873,008.07. The trade was a 1.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Over the last three months, insiders have purchased 220,000 shares of company stock worth $147,635. 41.10% of the stock is owned by company insiders.

Nautilus Biotechnology Stock Down 3.2%

Shares of NAUT opened at $0.80 on Tuesday. The stock has a market capitalization of $101.33 million, a P/E ratio of -1.54 and a beta of 1.42. Nautilus Biotechnology, Inc. has a twelve month low of $0.62 and a twelve month high of $3.03. The company has a 50 day moving average of $0.72 and a 200-day moving average of $0.76.

Nautilus Biotechnology (NASDAQ:NAUT) last issued its quarterly earnings results on Thursday, July 31st. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.02. On average, sell-side analysts anticipate that Nautilus Biotechnology, Inc. will post -0.57 earnings per share for the current fiscal year.

Nautilus Biotechnology Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.